Texas Senate · 89th Legislature, Regular Session
Members who authored, joint-authored, or co-sponsored this bill.
SourceLegiScan (CC BY 4.0)89R
AI summary unavailable. We’re still building out our data, so newer and more active legislation has better coverage.
Each version links to the authoritative document on capitol.texas.gov.
89R7809 DNC-D By: Menéndez S.B. No. 1688 A BILL TO BE ENTITLED AN ACT relating to health benefit plan coverage of anxiety and pain management in connection with prescription contraceptive devices. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. Section 1369.1031, Insurance Code, is amended by adding Subsections (e) and (f) to read as follows: (e) A health benefit plan that provides benefits for forms
of contraception approved by the United States Food and Drug Administration must provide coverage of evidence-based anxiety and pain management related to the insertion and removal of contraception, including: (1) prescription antianxiety medication; (2) minimal and moderate sedation; (3) local anesthesia; (4) topical anesthetics; and (5) paracervical blocks. (f) The coverage described by Subsection (e) is not subject to a cost-sharing requirement, including a deductible or coinsurance, utilization review, or step therapy, or any other restriction or delay on coverage. SECTION 2. The change in law made by this Act applies only to a health benefit plan that is delivered, issued for delivery, or renewed on or after January 1, 2026. SECTION 3. This Act takes effect September 1, 2025.
SourceTexas Legislative Council (capitol.texas.gov)official bill text (capitol.texas.gov)
Each subject links to other 89R bills tagged the same way.
SourceLegiScan (CC BY 4.0)subject tags
SourceTexas Legislative Council (capitol.texas.gov)89R
No recorded roll-call votes on this bill.
SourceLegiScan (CC BY 4.0)89R
No fiscal notes or analyses recorded for this bill.
SourceLegiScan (CC BY 4.0)official fiscal notes & analyses (TLC)
Perch never collects comments itself — it points you to the Legislature's own hearing schedule and official public-comment channels (ADR-0007).